CXCR1 and chronic obstructive pulmonary disease: Although reparixin, a dual blocker of CXCR1-CXCR2, was efficient in our in vitro experiments to block the increased chemotaxis of fibrocytes towards secretion of COPD CD8+ T cells, the in vivo effect of this therapy predicted using our computational model was moderate, highlighting the importance of this integrated approach.